Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 29, 2008
Business Overview: Haemonetics is a global leader in blood management solutions, operating as a single segment focused on automated blood processing systems. The company serves three product families: Donor (plasma, blood bank, and red cell collection), Patient (surgical blood salvage and diagnostics), and Software/Services (IT platforms and consulting). Principal operations are located in the U.S., Europe, Japan, and Asia.
Key Financial Metrics
| Metric (in thousands) | Fiscal 2008 | Fiscal 2007 | Fiscal 2006 |
|---|---|---|---|
| Net Revenues | $516,440 | $449,607 | $419,733 |
| Gross Profit | $257,725 | $227,300 | $220,535 |
| Gross Margin | 49.9% | 50.6% | 52.5% |
| Operating Income | $70,287 | $62,745 | $98,338 |
| Operating Margin | 13.6% | 14.0% | 23.4% |
| Net Income | $51,980 | $49,109 | $68,396 |
| Diluted EPS | $1.94 | $1.78 | $2.49 |
| Cash & Equivalents | $133,553 | $229,227 | $250,667 |
| Total Debt | $12,363 | $28,876 | $39,153 |
| Working Capital | $261,757 | $321,654 | $330,288 |
| Current Ratio | 3.7 | 4.9 | 4.7 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 14.9% to $516.4 million, driven by a 12.8% increase in disposable sales (86% of total revenue) and a 47.6% increase in equipment sales. Foreign exchange contributed a 2.2% favorable impact.
- Profitability: Operating income rose 12.0% to $70.3 million. This growth was aided by the absence of a $9.1 million in-process R&D charge recorded in FY2007 related to the Arryx acquisition. However, Selling, General, and Administrative (SG&A) expenses increased 19.0% due to ERP implementation costs ($7.5 million) and acquisition-related expenses.
- Acquisitions: The company acquired Haemoscope Corporation's TEG business (blood diagnostics) for approximately $45.6 million in November 2007 and Infonale (blood management consulting) for $1.3 million in July 2007. These acquisitions contributed to revenue growth in the Patient and Software segments.
- Geographic Mix: International revenues accounted for 55% of total sales. Japan remained a significant market, with the Japanese Red Cross representing 14.2% of total net revenues.
Guidance, Outlook, and Risks
- Outlook: Management expects the reported tax rate for fiscal 2009 to be approximately 34.5% to 35.0%. The company plans to continue investing in R&E for next-generation donor apheresis platforms and the Cymbal red cell collection system.
- Capital Allocation: A new $60 million share repurchase program was authorized in April 2008, with repurchases commencing in May 2008. Capital expenditures increased to $57.8 million in FY2008, primarily for device placement and ERP systems.
- Key Risks:
- Customer Concentration: The Japanese Red Cross is a significant customer; loss of this relationship or regulatory changes in Japan could materially impact revenue.
- Foreign Exchange: Approximately 55% of sales are in foreign currencies (primarily Euro and Yen). A strengthening U.S. dollar could adversely affect reported results.
- Regulatory: Products are subject to strict FDA and international regulations. Delays in approvals or adverse regulatory actions could hinder growth.
- Competition: The company faces competition from Fenwal, Gambro BCT, and others in specific product lines, particularly in automated plasma and platelet collection.
- Legal Proceedings: The company settled a claim against Baxter for $6 million in FY2007. In April 2008, a subsidiary in Italy was found guilty of charges related to improper payments; the company plans to appeal, and management believes the outcome will not materially affect financial position.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the relationship with the Japanese Red Cross (14.2% of revenue) and potential regulatory risks in Japan.
- Acquisition Integration: Assess the financial performance and integration progress of the Haemoscope (TEG) and Infonale acquisitions.
- ERP Implementation: Monitor the impact of the new global ERP system on operating costs and efficiency, given the $7.5 million expense in FY2008.
- Foreign Exchange Exposure: Review hedging strategies and the sensitivity of earnings to fluctuations in the Euro and Japanese Yen.
- Share Repurchases: Track the execution of the new $60 million share repurchase program authorized in May 2008.
- Legal Contingencies: Follow the status of the Italian legal proceedings and the appeal process.